Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 247 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pruritis Clear all
Completed Phase 4 Interventional Results available

Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

NCT01712360
View directory record Official record
Conditions
Tinea Pedis, Tinea Cruris
Interventions
NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult), NAFT600 (adult)
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jun 10, 2026, 6:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

NCT00275795
View directory record Official record
Conditions
Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions
NAET Procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
2 Years to 78 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2006 · Synced Jun 10, 2026, 6:00 PM EDT
Recruiting Not applicable Interventional

VR-PMR for Post-Burn Symptoms

NCT07317271
View directory record Official record
Conditions
Burn, Chronic Pain Following Thermal Burn Injury, Non-Pharmacological Interventions, Virtual Reality, Sleep Disturbance, Anxiety, Depressive Symptoms, Fatigue Symptom, Pruritus, Burn Injury, Progressive Muscle Relaxation
Interventions
Virtual Reality-Enhanced Progressive Muscle Relaxation, Standard Progressive Muscle Relaxation
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Not applicable Interventional Results available

The CO2RE® System for Vulvar Lichen Sclerosus

NCT04148651
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
The CO2RE® System
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

NCT01806597
View directory record Official record
Conditions
Moderate to Severe Palmoplantar Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jun 10, 2026, 6:00 PM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jun 10, 2026, 6:00 PM EDT
Completed No phase listed Observational

Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes

NCT01679015
View directory record Official record
Conditions
Dry Eyes, Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
Schwartz Laser Eye Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jun 10, 2026, 6:00 PM EDT
Terminated Early Phase 1 Interventional

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169
View directory record Official record
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica

NCT06262607
View directory record Official record
Conditions
Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP)
Interventions
CLE-400, Vehicle
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
13
States / cities
Bryant, Arkansas • Fremont, California • Coral Gables, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 10, 2026, 6:00 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jun 10, 2026, 6:00 PM EDT
Recruiting Phase 3 Interventional

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

NCT05677451
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
12
States / cities
Bakersfield, California • San Diego, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 6:00 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

NCT03540160
View directory record Official record
Conditions
Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions
5 mg Serlopitant Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
46
States / cities
Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Not applicable Interventional Results available

The Role of Skin Care Regimen in Skin Health

NCT03497130
View directory record Official record
Conditions
Itching, Xerosis
Interventions
skin care regimen
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines

NCT05030311
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
26
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Jun 10, 2026, 6:00 PM EDT
Not listed Phase 4 Interventional

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy
Drug · Device
Lead sponsor
OptiSkin Medical
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Jun 10, 2026, 6:00 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

NCT01625455
View directory record Official record
Conditions
Sezary Syndrome, Pruritus
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

NCT04490109
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jun 10, 2026, 6:00 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 6:00 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
34
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 6:00 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

NCT00863395
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
skin biopsy
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Jun 10, 2026, 6:00 PM EDT
Completed No phase listed Observational

Scratch and Sleep Quantification in Atopic Dermatitis

NCT03490877
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Sleep Disturbance
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jun 10, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema

NCT02691507
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jun 10, 2026, 6:00 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Standard of Care
Biological · Other
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 6:00 PM EDT